16729-117 : Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution


NDC16729-117
Labeler: Accord Healthcare, Inc.
Product Type: Human Prescription Drug
Drug Name:  Gemcitabine Hydrochloride
Dosage Form: Intravenous Injection, Powder, Lyophilized, for Solution
Application #: ANDA091594
Rev. Date: 


NDC Package Codes:

  • 16729-117-11: 1 VIAL IN 1 CARTON (16729‑117‑11) > 25 ML IN 1 VIAL

Active Ingredients:

  • Gemcitabine Hydrochloride

Dosage Strength:

  • 1 g/25mL

Pharmaceutical Classes:

  • Nucleic Acid Synthesis Inhibitors [MoA]
  • Nucleoside Metabolic Inhibitor [EPC]

Related Products:

Based on records with the same trade name.
  • 16729-092 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Accord Healthcare, Inc.
  • 16729-118 Gemcitabine Hydrochloride 2 g/50ml Intravenous Injection, Powder, Lyophilized, for Solution by Accord Healthcare, Inc.
  • 0069-3857 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Pfizer Laboratories Div Pfizer Inc.
  • 0069-3858 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Pfizer Laboratories Div Pfizer Inc.
  • 0069-3859 Gemcitabine Hydrochloride 2 g/50ml Intravenous Injection, Powder, Lyophilized, for Solution by Pfizer Laboratories Div Pfizer Inc.
  • 0591-3562 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Watson Laboratories, Inc.
  • 0591-3563 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Watson Laboratories, Inc.
  • 0703-5775 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Teva Parenteral Medicines, Inc.
  • 0703-5778 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Teva Parenteral Medicines, Inc.
  • 23155-213 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc.
  • 23155-214 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc.
  • 23155-483 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc.
  • 23155-484 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc.
  • 23155-528 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc.
  • 23155-529 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Heritage Pharmaceuticals Inc.
  • 42236-001 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Hameln Rds Gmbh
  • 42236-002 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Hameln Rds Gmbh
  • 45963-612 Gemcitabine Hydrochloride 200 mg/5ml Intravenous Injection, Powder, Lyophilized, for Solution by Actavis Pharma, Inc.
  • 45963-619 Gemcitabine Hydrochloride 1 g/25ml Intravenous Injection, Powder, Lyophilized, for Solution by Actavis Pharma, Inc.
  • 45963-620 Gemcitabine Hydrochloride 2 g/50ml Intravenous Injection, Powder, Lyophilized, for Solution by Actavis Pharma, Inc.
  • More related products ...

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 16729-117 QR Code

< Prev: 16729-116Next: 16729-118 >

Related Discussions:

GEMCITABINE/GEMZAK
CHEMOTHERAPY ## What is the dosage of gemcitabin + Mannitol +Sodium Acetate Combination... 1 reply




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.